78 related articles for article (PubMed ID: 2654403)
1. Cisplatin in the treatment of solid tumors: effect of dose and schedule.
Livingston RB
J Natl Cancer Inst; 1989 May; 81(10):724-5. PubMed ID: 2654403
[No Abstract] [Full Text] [Related]
2. Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes.
Pentheroudakis G; Briasoulis E; Karavassilis V; Mauri D; Tzamakou E; Rammou D; Pavlidis N
Chemotherapy; 2005 May; 51(2-3):154-61. PubMed ID: 15886476
[TBL] [Abstract][Full Text] [Related]
3. Dose and schedule effects of cisplatin on the related acute iron changes.
Pollera CF; Ameglio F; Nardi M; Marolla P; Carlini P; Frasca AM
Oncology; 1990; 47(2):133-8. PubMed ID: 2314826
[TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine in patients with advanced solid tumors.
Fakih MG; Creaven PJ; Ramnath N; Trump D; Javle M; Strychor S; Repinski TV; Zamboni BA; Schwarz JK; French RA; Zamboni WC
Clin Cancer Res; 2005 Aug; 11(16):5942-9. PubMed ID: 16115937
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I study.
Specenier P; Rasschaert M; Van den Brande J; Dyck J; Schrijvers D; Huizing MT; Vermorken JB
Anticancer Drugs; 2010 Mar; 21(3):306-12. PubMed ID: 20087171
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors.
Saltz LB; Spriggs D; Schaaf LJ; Schwartz GK; Ilson D; Kemeny N; Kanowitz J; Steger C; Eng M; Albanese P; Semple D; Hanover CK; Elfring GL; Miller LL; Kelsen D
J Clin Oncol; 1998 Dec; 16(12):3858-65. PubMed ID: 9850031
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of weekly irinotecan combined with weekly cisplatin in patients with advanced solid tumors.
Nakanishi Y; Takayama K; Wataya H; Izumi M; Minami T; Takano K; Inoue K; Osaki S; Kimotsuki K; Harada T; Hara N
Chemotherapy; 2002 Sep; 48(4):205-10. PubMed ID: 12218268
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors.
Fury MG; Sherman E; Haque S; Korte S; Lisa D; Shen R; Wu N; Pfister D
Cancer Chemother Pharmacol; 2012 Mar; 69(3):591-8. PubMed ID: 21913034
[TBL] [Abstract][Full Text] [Related]
9. Platinum dose-intensity in solid tumors: pharmacological and clinical perspectives.
Pagani O; Sessa C; Cavalli F
Bull Cancer; 1995; 82 Suppl 1():16s-23s. PubMed ID: 7626849
[No Abstract] [Full Text] [Related]
10. Pharmacokinetic evaluation of cisplatin in children with malignant solid tumors: a phase II study.
Pratt CB; Hayes A; Green AA; Evans WE; Senzer N; Howarth CB; Ransom JL; Crom W
Cancer Treat Rep; 1981; 65(11-12):1021-6. PubMed ID: 7197583
[TBL] [Abstract][Full Text] [Related]
11. Use of cisplatin for elderly patients.
Lichtman SM; Buchholtz M; Marino J; Schulman P; Allen SL; Weiselberg L; Budman D; DeMarco L; Schuster M; Lovecchio J
Age Ageing; 1992 May; 21(3):202-4. PubMed ID: 1615783
[TBL] [Abstract][Full Text] [Related]
12. A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors.
Felici A; Loos WJ; Verweij J; Cirillo I; de Bruijn P; Nooter K; Mathijssen RH; de Jonge MJ
Cancer Chemother Pharmacol; 2006 Nov; 58(5):673-80. PubMed ID: 16544143
[TBL] [Abstract][Full Text] [Related]
13. Modulation of cell cycle progression in human tumors: a pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850).
Perez RP; Lewis LD; Beelen AP; Olszanski AJ; Johnston N; Rhodes CH; Beaulieu B; Ernstoff MS; Eastman A
Clin Cancer Res; 2006 Dec; 12(23):7079-85. PubMed ID: 17145831
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study.
Lilenbaum RC; Miller AA; Batist G; Bernard S; Hollis DR; Rosner GL; Egorin MJ; Schilsky RL; Ratain MJ
J Clin Oncol; 1998 Oct; 16(10):3302-9. PubMed ID: 9779705
[TBL] [Abstract][Full Text] [Related]
15. Weekly administration of cis-dichlorodiammineplatinum(II) in childhood solid tumors: a Southwest Oncology Group study.
Nitschke R; Fagundo R; Berry DH; Falletta JM
Cancer Treat Rep; 1979 Mar; 63(3):497-9. PubMed ID: 427829
[No Abstract] [Full Text] [Related]
16. Evaluation of cisplatin dose intensity: current status and future prospects.
Gandara DR; Perez EA; Phillips WA; Lawrence HJ; DeGregorio M
Anticancer Res; 1989; 9(4):1121-8. PubMed ID: 2683991
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
Miller AA; Hargis JB; Lilenbaum RC; Fields SZ; Rosner GL; Schilsky RL
J Clin Oncol; 1994 Dec; 12(12):2743-50. PubMed ID: 7527456
[TBL] [Abstract][Full Text] [Related]
18. [Prevention of cisplatin nephrotoxicity in cancer: adjusting the dosage with a computerized chrono-pump].
Gestin-Boyer C; René C; Cupissol D; Tep A; Bressolle F; Bres J; Brun S; Serrou B; Pujol H
C R Seances Soc Biol Fil; 1989; 183(3):263-8. PubMed ID: 2532561
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignancies.
Bilenker JH; Stevenson JP; Flaherty KT; Algazy K; McLaughlin K; Haller DG; Giantonio BJ; Koehler M; Garcia-Vargas JE; O'Dwyer PJ
Cancer Chemother Pharmacol; 2004 Apr; 53(4):357-60. PubMed ID: 14722734
[TBL] [Abstract][Full Text] [Related]
20. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
